Type 2 Diabetes Mellitus Treatment Market By Therapeutic Class (GLP-1 Receptor Agonists, Dual GIP/GLP-1 Agonists, SGLT2 Inhibitors, Insulin Therapies, DPP-4 Inhibitors, Metformin, Sulfonylureas, Fixed-Dose and Fixed-Ratio Combinations, Others); By Route and Treatment Format (Oral Therapies, Daily Injectable Therapies, Weekly Injectable Therapies, Combination Therapies); By Patient Risk and Treatment Need (Obesity-Associated Type 2 Diabetes, Cardiovascular-Risk Patients, Chronic Kidney Disease and Heart-Failure Patients, Insulin-Treated Type 2 Diabetes, Newly Diagnosed and Early-Stage Patients, Poorly Controlled and Therapy-Escalation Patients); By Care and Technology Layer (Drug Therapy, Continuous Glucose Monitoring-Supported Care, Automated Insulin Delivery-Supported Care, Connected Pens and Digital Titration Support); By Distribution and Access Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Programs and Institutional Procurement); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Type 2 Diabetes Mellitus Treatment Market: GLP-1 Scale, Organ-Protection Prescribing, and Weekly Insulin Reshape Chronic Metabolic Care

The Global Type 2 Diabetes Mellitus Treatment Market was valued at USD 58.2 billion in 2025 and is projected to reach USD 103.24 billion by 2032, growing at a CAGR of 8.45%, according to Strategic Market Research.

 

Type 2 diabetes mellitus treatment is moving beyond glucose control as obesity, cardiovascular risk, kidney disease, insulin adherence, and long-term treatment persistence become central prescribing factors. WHO estimates that 830 million people were living with diabetes in 2022, up from about 200 million in 1990. Adult prevalence doubled from 7% to 14% over the same period. Type 2 diabetes accounts for more than 95% of diabetes cases, making it the main driver of drug demand, monitoring spend, primary-care burden, and complication-related healthcare costs.

 

Available drug classes have not eliminated the substantial unmet treatment need.WHO reported that more than half of adults aged 30 years and older with diabetes were not taking diabetes medication in 2022. IDF’s 2025 Atlas estimated 589 million adults aged 20–79 with diabetes in 2024 and projected 853 million by 2050. Therapy demand is expanding through more diagnosis, treatment intensification after poor glycemic control, obesity-linked prescribing, and broader use of GLP-1 receptor agonists, SGLT2 inhibitors, insulin, continuous glucose monitoring, and combination metabolic care.

 

Untreated and Poorly Controlled Patients Keep Therapy Escalation High

Type 2 diabetes drug demand is shaped by missed diagnosis, weak persistence, affordability barriers, and incomplete target achievement. A Global Burden of Disease care-cascade analysis estimated that only 21.2% of people with diabetes had optimal glycemic concentrations while receiving treatment in 2023. Although the figure includes both type 1 and type 2 diabetes, adult type 2 diabetes dominates the global case base. Poor glycemic control creates repeated therapy escalation, additional combination prescribing, injectable conversion, digital monitoring, and complication-prevention spending.

The U.S. remains one of the most valuable diabetes treatment markets because prevalence, diagnosis, reimbursement, and drug spending are all high. CDC’s 2026 National Diabetes Statistics Report estimated 40.1 million people with diagnosed or undiagnosed diabetes in 2023, equal to 12.0% of the U.S. population. CDC also estimated that 27.6% of U.S. adults with diabetes were undiagnosed, representing 11.0 million people, while 115.2 million adults had prediabetes. Diagnosed patients drive current drug utilization, while undiagnosed diabetes and prediabetes expand the future pool for screening, early therapy, prevention programs, and payer-led intervention.

The high cost of diabetes-related complications gives U.S. payers a strong financial rationale to prioritize therapies that improve long-term outcomes. The American Diabetes Association estimated the annual cost of diagnosed diabetes in the U.S. at USD 412.9 billion in 2022, including USD 306.6 billion in direct medical costs and USD 106.3 billion in indirect costs. People with diagnosed diabetes accounted for one in four U.S. healthcare dollars, and average medical expenditures were 2.6 times higher than expected without diabetes. Products with evidence in hospitalization reduction, kidney protection, heart-failure prevention, weight reduction, and delayed insulin intensification have stronger reimbursement logic than drugs positioned only around HbA1c lowering.

 

GLP-1 and SGLT2 Therapy Are Becoming Core Prescribing Classes

GLP-1 receptor agonists and SGLT2 inhibitors are moving from specialist-led intensification into mainstream type 2 diabetes care because guidelines now place cardiovascular disease, chronic kidney disease, heart failure, obesity, and high-risk status at the center of drug selection. CDC researchers estimated that 82% of U.S. adults with type 2 diabetes could be eligible for a GLP-1 receptor agonist, an SGLT2 inhibitor, or both under ADA/EASD criteria. Only 9% used either class during 2017–2020, leaving a wide gap between guideline eligibility and actual prescribing.

GLP-1 uptake has accelerated sharply since that earlier eligibility estimate. CDC’s 2025 NCHS Data Brief reported that 26.5% of U.S. adults with diagnosed diabetes used GLP-1 injectables in 2024. Use was higher among adults with obesity at 32.4%, insulin users at 31.3%, and adults using oral glucose-lowering drugs at 28.1%. The same CDC brief cited a 155% increase in GLP-1 injectable use among adults with type 2 diabetes from 2018 to 2022 and more than 500% growth in GLP-1 medication spending from 2018 to 2023. GLP-1 products are changing both treatment practice and the diabetes spending mix.

SGLT2 inhibitors occupy a different position from GLP-1 therapies. Weight loss is not their main commercial narrative; kidney and heart-failure protection are. EMPA-REG OUTCOME established the category’s high-risk cardiovascular value by showing that empagliflozin reduced cardiovascular death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes and established cardiovascular disease. Guideline use has since expanded because kidney disease progression and heart failure are major cost drivers in diabetes care.

Semaglutide’s FLOW trial extended GLP-1 positioning into renal-risk management. In patients with type 2 diabetes and chronic kidney disease, semaglutide reduced the risk of major kidney disease events or cardiovascular death by 24%. Kidney-risk reduction is commercially important because diabetic kidney disease drives dialysis, specialist visits, hospitalization, and long-term payer exposure. GLP-1 competition is now being judged through cardiorenal outcomes, weight reduction, tolerability, persistence, and payer access, not only glycemic efficacy.

 

Incretin Franchises Are Competing on Weight, Route, Outcomes, and Scale

Competition in the GLP-1 market now extends across multiple molecules and delivery formats. Novo Nordisk, Eli Lilly, and emerging metabolic-therapy developers are competing across injectable GLP-1s, dual agonists, triple agonists, oral small molecules, amylin combinations, and less-frequent dosing. Product selection is increasingly tied to weight reduction, HbA1c depth, cardiovascular safety, kidney outcomes, gastrointestinal tolerability, route of administration, supply reliability, and affordability.

Tirzepatide’s SURPASS-CVOT study raised the evidence standard for next-generation incretin therapies. The trial compared tirzepatide with dulaglutide in more than 13,000 people with type 2 diabetes and established cardiovascular disease. The primary endpoint occurred in 12% of tirzepatide-treated patients and 13% of dulaglutide-treated patients, with a hazard ratio of 0.92. Noninferiority was met, while superiority was not statistically established. Mature incretin competition will depend on total metabolic value, not cardiovascular safety alone.

Retatrutide is pushing the next competitive threshold. Lilly reported that TRANSCEND-T2D-1, a Phase 3 trial in adults with type 2 diabetes, delivered average HbA1c reductions of up to 2.0 percentage points and average weight loss of 36.6 lb, or 16.8%, at 40 weeks. Retatrutide remains investigational for type 2 diabetes, but triple agonism could become a major escalation route for patients needing both glucose and obesity control.

CagriSema adds pressure to the high-efficacy injectable segment. In the Phase 3 REIMAGINE 2 trial, Novo Nordisk reported that CagriSema produced an HbA1c reduction of 1.91 percentage points and weight loss of 14.2% in adults with type 2 diabetes, outperforming semaglutide 2.4 mg on both measures. Combination incretin-amylin therapy could help Novo Nordisk defend premium positioning if stronger dual outcomes are achieved without unacceptable tolerability or access barriers.

Oral GLP-1 therapy could alter patient acceptance and manufacturing economics. Lilly reported that orforglipron, an oral small-molecule GLP-1, lowered HbA1c by 1.3 to 1.6 percentage points in the ACHIEVE-1 Phase 3 diabetes trial and produced average weight loss of 16.0 lb, or 7.9%, at the highest dose. FDA approval of orforglipron under the brand Foundayo in April 2026 was for chronic weight management, not type 2 diabetes. The diabetes opportunity sits in the ACHIEVE program and the possibility that oral small molecules can reduce injection resistance, cold-chain pressure, and biologic supply constraints.

 

Once-Weekly Basal Insulin Targets Insulin Delay and Injection Fatigue

Insulin remains essential for many people with long-duration type 2 diabetes, but delayed initiation, missed doses, fear of hypoglycemia, and injection fatigue continue to weaken outcomes. FDA listed Awiqli, insulin icodec-abae, among 2026 novel approvals, with an indication to improve glycemic control in adults with type 2 diabetes mellitus. Once-weekly basal insulin changes the treatment burden by reducing basal administration from daily injections to one dose per week.

Novo Nordisk’s India launch gives weekly insulin a stronger foothold in emerging-market diabetes care. Awiqli was launched in India in July 2026, reducing annual insulin injections from 365 to 52. The company priced a 70-unit weekly dose at Rs. 261, with 1 ml and 3 ml pen variants priced at Rs. 2,611 and Rs. 7,833. India became the seventh country where Novo Nordisk launched Awiqli, and the addressable insulin-user base is substantial, with around 6 million Indians currently using insulin therapy and the company expecting the figure to rise to 9 million. Weekly basal insulin can reduce injection burden, but uptake will depend on pricing, physician comfort, hypoglycemia management, pharmacy reach, and how quickly endocrinologists shift suitable patients from daily basal regimens.

Low-cost basal insulin, human insulin, biosimilars, and fixed-ratio combinations will remain important in cost-sensitive markets. Weekly insulin will expand the intensification toolkit rather than replace daily basal insulin across all patient groups. Payers and physicians will use it where convenience, adherence, and delayed insulin initiation justify premium pricing or formulary inclusion.

 

India and China Are Moving Toward Localized GLP-1 Access

India has one of the world’s largest diabetes treatment gaps. The ICMR–INDIAB study estimated 101 million people with diabetes and 136 million with prediabetes in 2021. Scale alone makes India commercially important, but treatment adoption depends on affordability, urban-rural access, insulin hesitation, generic competition, physician education, and public-sector screening.

India’s National NCD Portal shows the expansion of chronic-disease registration. The portal reported 76.94 crore beneficiaries enrolled, 9.36 crore patients under treatment for hypertension and diabetes combined, and adoption across 31 states and union territories. The headline treatment figure should not be treated as a diabetes-only count because the portal combines hypertension and diabetes. For market analysis, the portal is better read as evidence of chronic-care infrastructure expansion and public-sector patient capture.

Semaglutide access in India is shifting toward domestic competition. CDSCO’s March 2026 endocrinology and metabolism recommendations accepted Phase 3 clinical trial reports and recommended permission for manufacture and marketing of synthetic-origin semaglutide injection for type 2 diabetes for Hetero Labs, with post-marketing and PSUR conditions. Intas was also listed in the same meeting recommendations for semaglutide injection in type 2 diabetes. Domestic approval activity suggests that India’s GLP-1 market will become more price-competitive, while quality, supply consistency, pharmacovigilance, and device reliability separate durable suppliers from short-cycle entrants.

China is using public formulary policy to widen GLP-1 access. Reuters reported in July 2026 that China would add semaglutide to its National Essential Drug List under insulin and blood-glucose-lowering medication, effective September 1. Public hospitals are expected to prioritize listed products, and the move could support broader generic inclusion after approvals. China already has the largest adult diabetes population by IDF estimates, so essential-list placement can move GLP-1 demand from urban specialty use toward broader public-hospital availability.

 

Europe’s Audit Systems Expose the Control Gap

Europe has a large reimbursed diabetes population, but structured care has not eliminated poor control. IDF estimates that 66 million adults in Europe have diabetes, one in three adults living with diabetes are undiagnosed, and diabetes-related expenditure reached USD 193 billion in 2024, equal to 19% of global diabetes expenditure. Aging populations, obesity, treatment persistence, and cardiovascular risk continue to pressure national health budgets.

England’s National Diabetes Audit provides a practical benchmark for treatment quality. In the financial year ending March 2025, 64.7% of people with type 2 and other diabetes achieved HbA1c of 58 mmol/mol or less. Only 45.2% achieved all three assessed treatment targets: HbA1c, blood pressure, and statin prescription. Even in an audit-led healthcare system, more than half of patients did not reach the full cardiometabolic target bundle. Therapies and care models that address glucose, blood pressure, lipids, weight, and kidney risk together have stronger relevance for payers than narrow glucose-only approaches.

 

Asia Pacific Carries the Largest Volume Opportunity

Asia Pacific carries the strongest long-term volume opportunity because China, India, Southeast Asia, and Western Pacific countries combine large populations, urbanization, obesity growth, aging, and expanding diagnosis. IDF reports that the Western Pacific region has 215 million adults with diabetes, accounting for 37% of the global adult diabetes population. China alone accounts for roughly one in four adults with diabetes worldwide.

South-East Asia is a faster-growth treatment region. IDF estimates that 107 million adults in South-East Asia have diabetes and projects a 73% increase to 185 million by 2050. Nearly 42.7% of adults living with diabetes in the region are undiagnosed. India accounts for one in seven adults living with diabetes worldwide. Treatment growth in this region will come from diagnosis expansion, low-cost oral therapy, basal insulin access, domestic GLP-1 supply, pharmacy reach, and public screening programs rather than premium biologics alone.

 

Monitoring and Automated Insulin Delivery Are Entering Type 2 Care

Digital diabetes tools are moving from type 1 diabetes into insulin-treated and poorly controlled type 2 diabetes. ADA’s 2026 Standards of Care summary expanded continuous glucose monitoring recommendations, including use at diabetes onset and later for children, adolescents, and adults when likely to benefit. Broader CGM use can increase demand for sensors, connected pens, adherence platforms, insulin-titration services, and population-management programs.

Automated insulin delivery is also being tested in type 2 diabetes. Diabetes Care published 2026 evidence indicating that AID systems improved glucose control in a diverse population of people with type 2 diabetes requiring insulin therapy, with reduced hyperglycemia and no increase in hypoglycemia. Insulin-intensive type 2 diabetes patients create a practical use case because dose adjustment, missed injections, fear of hypoglycemia, and monitoring fatigue contribute to avoidable poor control.

AI-based diabetes tools remain early but strategically relevant for screening, risk stratification, and treatment support. A 2026 machine-learning model presented at ADA analyzed records from 3.37 million adults and predicted type 2 diabetes risk up to ten years in advance, with an area under the curve of 0.883. Health systems and payers may use predictive models to direct prevention, early therapy, and follow-up programs toward patients with the highest near-term risk.

 

Competitive Positioning Is Shifting Toward Metabolic Platforms

Novo Nordisk remains strongly positioned through semaglutide, insulin icodec, CagriSema, and a deep diabetes infrastructure. Incretin leadership, insulin experience, physician familiarity, and global commercial reach support its position. Supply reliability and pricing pressure will matter more as semaglutide competition increases in India, China, and other patent-expiry markets.

Eli Lilly is shaping the highest-growth side of the category through tirzepatide, orforglipron, and retatrutide. Its portfolio spans injectable dual agonism, oral GLP-1 therapy, and investigational triple agonism. Lilly’s main challenge is managing indication sequencing, manufacturing scale, tolerability, payer access, and the positioning of retatrutide without eroding existing incretin revenue too quickly.

AstraZeneca, Boehringer Ingelheim, and other SGLT2 leaders remain important because heart failure and kidney disease have made SGLT2 inhibitors foundational in high-risk type 2 diabetes. Generic metformin, sulfonylureas, DPP-4 inhibitors, and insulin will remain essential in cost-sensitive markets. Premium growth is concentrated in GLP-1s, GIP/GLP-1 agents, SGLT2 inhibitors, weekly insulin, CGM, and combination metabolic care.

Indian and Chinese manufacturers are becoming more important as semaglutide, SGLT2, and insulin markets localize. Domestic companies can compete through lower pricing, broader retail reach, and public-market access. Sustainable positioning will depend on quality standards, pharmacovigilance, device reliability, API continuity, and physician trust.

 

Strategic Outlook

Type 2 diabetes treatment is being upgraded from a glucose-lowering sequence into a metabolic-risk management model. Weight reduction, kidney protection, heart-failure prevention, cardiovascular risk control, injection burden, monitoring data, and long-term persistence now shape prescribing and reimbursement.

GLP-1 and dual or triple incretin therapies are the strongest premium-growth segment because they address glycemia and obesity together. SGLT2 inhibitors retain durable value because kidney and heart-failure outcomes are now central to type 2 diabetes care. Once-weekly basal insulin addresses insulin hesitation and injection fatigue in patients who need intensification. CGM and automated insulin delivery create a technology layer around insulin-treated type 2 diabetes and poorly controlled populations.

Market leadership will depend on outcome evidence beyond HbA1c, supply scale, affordability, route convenience, payer access, and fit within cardiometabolic care pathways. Companies that combine metabolic efficacy, organ-protection evidence, convenient dosing, reliable manufacturing, and access discipline will be better positioned than suppliers relying only on single-molecule glucose reduction.

 

Type 2 Diabetes Mellitus Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 58.20 Billion
Revenue Forecast in 2032	USD 103.24 Billion
Overall Growth Rate	CAGR of 8.45% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Therapeutic Class, By Route and Treatment Format, By Patient Risk and Treatment Need, By Care and Technology Layer, By Distribution and Access Channel, By Geography
By Therapeutic Class	GLP-1 Receptor Agonists, Dual GIP/GLP-1 Agonists, SGLT2 Inhibitors, Insulin Therapies, DPP-4 Inhibitors, Metformin, Sulfonylureas, Fixed-Dose and Fixed-Ratio Combinations, Others
By Route and Treatment Format	Oral Therapies, Daily Injectable Therapies, Weekly Injectable Therapies, Combination Therapies
By Patient Risk and Treatment Need	Obesity-Associated Type 2 Diabetes, Cardiovascular-Risk Patients, Chronic Kidney Disease and Heart-Failure Patients, Insulin-Treated Type 2 Diabetes, Newly Diagnosed and Early-Stage Patients, Poorly Controlled and Therapy-Escalation Patients
By Care and Technology Layer	Drug Therapy, Continuous Glucose Monitoring-Supported Care, Automated Insulin Delivery-Supported Care, Connected Pens and Digital Titration Support
By Distribution and Access Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Programs and Institutional Procurement
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising global diabetes prevalence Increasing obesity-linked metabolic disorders Expansion of GLP-1 and SGLT2 adoption
Customization Option	Available upon request